Medicines Co. (MDCO) Reports Q3 Loss Per Share of $1.19, Less Than Expected
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
The Medicines Company Reports Third-Quarter 2017 Business and Financial Results
October 25, 2017 7:00 AM EDTPARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) today reported its financial results for the third quarter ended September 30, 2017, and provided an update on its clinical and operational activities.
We made significant clinical and strategic progress during the third quarter, said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. We aggressively advanced start-up work for the inclisiran Phase III clinical program, preparing investigational siteswhich began screening patients in Septemberand manufacturing double-blind-packaged drug supply, and are pleased to announce... More
